AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05300776 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: M-ROSE analysis
Description: The M-ROSE analysis process consists of 3 procudures.~1. Specimen quality assessment. The BALF undergoes the process of smear, diff-quik stain, gram stain and are analyzed by experts to report the cytoloy and pathogen patterns to determine whether the sample is qualified according to the cell proportions. The qualified BALF samples are: squamous epithelial cell proportion\<1%, columnar epithelial cell proportion \<5% .~2. Distinguish infection and colonization. According to the cytoloy pattern, the proportion of neutrophils > 50% often strongly suggests pulmonary bacterial infection; Neutrophil phagocytosis proportion> 5% indicates infection, and phagocytosis of bacteria is the pathogen. Besides, fungal and hyphae can be found under the microscope.~3. Preliminary identification of infectious pathogens. Identify the infected bacteria and fungi, and the results are gram-positive cocci, gram-positive bacilli, gram-negative cocci, gram-negative bacilli, yeasts and molds.
Study NCT05971069 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group1
Description: Entire fluorescence defect on the Lt. lobe of liver → Preservation of the aberrant left hepatic artery
Study NCT05971069 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group2
Description: Partial fluorecence defect on the Lt. lobe of liver → Ligation of the aberrant left hepatic artery
Study NCT05971069 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group3
Description: No fluorescence defect on the Lt. lobe of liver → Ligation of the aberrant left hepatic artery
Study NCT06589271 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: human umbilical cord mesenchymal stem cell suspension
Description: 2 \* 10\^7 cells (2ml)
Study NCT06589271 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: total endoscopic extraction of lumbar nucleus pulposus
Description: hUC-MSCs are injected into the opposite side of the minimally invasive surgical site immediately after surgery, and the puncture needle remains for 1 minute after injection and then pull out to prevent cell suspension leakage
Study NCT06663384 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evaluation of Augmented Reality technology in TKA compared to standard TKA
Description: Evaluation of effectiveness of AR system used to perform bone cuts when compared to traditional jigs in primary TKA
Study NCT06663384 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Evaluation of Augmented Reality technology in TKA compared to standard TKA
Description: Evaluation of effectiveness of AR system used to perform bone cuts when compared to traditional jigs in primary TKA
Study NCT06665009 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Manually Opened and Device-Opened Ampoules
Description: this study is to evaluate the ampoule peeling device in terms of safety, ease of use, time efficiency, difficulty of operation, and user satisfaction among nurses when opening ampoule bottles of different capacities
Study NCT05114031 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FB101
Description: Microbial intervention using product FB101
Study NCT05114031 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline water
Study NCT04738799 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Carbohydrate-Last Meal Sequence
Description: Carbohydrates consumed last during mealtimes for 6 days
Study NCT04738799 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Carbohydrate-First Meal Sequence
Description: Carbohydrates consumed first during mealtimes for 6 days
Study NCT05507346 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cross over Device (PCD or Dayspring - alternate to first group)
Description: Cross over after three month of use and a month of washout period
Study NCT05507346 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cross over Device (PCD or Dayspring - alternate to first group)
Description: Cross over after three month of use and a month of washout period
Study NCT04944173 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy
Description: Subjects will receive stereotactic radiation therapy concurrent with cycle 2 of durvalumab to a dose of 48Gy in four fractions. Fractionation may be modified for central tumors.
Study NCT04944173 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Circulating Tumor DNA assay
Description: After four cycles of durvalumab, subjects will be evaluated at the MRD Landmark for residual ctDNA to determine subsequent treatment assignment.
Study NCT05585840 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biofeedback-based virtual reality game
Description: The application will be a biofeedback-based virtual reality game developed by the researchers in collaboration with engineering in line with the literature review.
Study NCT06310616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VH4524184
Description: VH4524184 will be administered.
Study NCT06310616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loestrin
Description: Loestrin will be administered.
Study NCT04847674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEV-53275 Dose A
Description: subcutaneous (sc) injection
Study NCT04847674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEV-53275 Dose B
Description: subcutaneous (sc) injection
Study NCT04847674 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching subcutaneous (sc) placebo injection
Study NCT06122207 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Description: * Women: 1 capsule of probiotic (Ligilactobacillus salivarius PS11610) every 12 hours for 6-months. In case of pregnancy:~  * Women: 1 capsule of probiotic per day for 12 weeks.~* Men: 1 capsule of probiotic (Ligilactobacillus salivarius PS11610) per day for 6-months.
Study NCT06122207 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: * Women: 1 capsule of placebo every 12 hours for 6-months. In case of pregnancy:~  * Women:1 capsule of placebo per day for 12 weeks.~* Men: 1 capsule of placebo per day for 6-months.
Study NCT05534763 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IERGD
Description: A 10 week behavioral treatment focusing on gender minority stress, maladaptive and adaptive emotion regulation, emotional awareness, the functionality of emotions, interpersonal skills and values and valued actions.
Study NCT05534763 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: IER SUPPORT
Description: A 5-week behavioral course for a designated support person (family, friend, other) to the person with GD. The course focuses on teachings on living with minority stress, maladaptive and adaptive emotion regulation, emotional awareness, validation, interpersonal skills and values.
Study NCT06450990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGY-1601-VT
Description: Live biotherapeutic product. The active product ingredient of the Investigational Medicinal Product (IMP) is the bacterial strain Lacticaseibacillus rhamnosus Lcr35.
Study NCT06450990 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PLACEBO
Description: Placebo
Study NCT06450990 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Placebo
Study NCT05140902 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Point-of-care Portable Perfusion Phantom (P4)
Description: P4 is a perfusion phantom developed by Dr. Harrison Kim that can significantly reduce variation in quantitating perfusion of human abdominal tissues across MRI scanners.
Study NCT04651660 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuro Cochlear Implant System
Description: Before the mastoidectomy, the ear canal is cleaned, the insert earphone is connected to the Eclipse (Oticon Medical software) preamplifier and placed into the ear canal. The EEG scalp electrodes (active, ground electrode) are placed on the patient's head. After the posterior tympanotomy, the reference electrode (eCochG probe) is placed on the cochlear promontory.~The CI electrode array will be inserted following one of the two possible techniques while the eCochG will be recording. The surgeon will either manually insert the array using the Oticon Medical stylet and following the surgery guides and recommendations from Oticon Medical or will control the Robotol insertion angle and drive the robotic arm in the same way.
Study NCT05123482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8205
Description: AZD8205 is an antibody drug conjugate that has the potential to treat a wide variety of solid tumors including but not limited to breast cancer, Biliary Tract Cancer, ovarian, and endometrial cancers
Study NCT05123482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8205 and AZD2936 (Rilvegostomig)
Description: AZD8205 is an antibody drug conjugate that has the potential to treat a wide variety of solid tumors including but not limited to breast cancer, Biliary Tract Cancer, ovarian, and endometrial cancers.~Rilvegostomig is a bispecific antibody that specifically binds to human TIGIT and PD-1 and is a potential anticancer therapy in patients with advanced or metastatic solid tumors.
Study NCT05415163 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: vascular photobiomodulation
Description: application of photobiomodulation with the device O Ecco ILIB (Eccofibras, São Paulo, Brazil) containing its red wavelength 660 nm ± 10 nm and power 100 mW, with an application time of 30 minutes. The device will be positioned with the spot located in the radial artery of the participant's arm (right or left), and fixed to the wrist with a specific bracelet.
Study NCT05415163 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: vascular photobiomodulation
Description: application of photobiomodulation with the device O Ecco ILIB (Eccofibras, São Paulo, Brazil) containing its red wavelength 660 nm ± 10 nm and power 100 mW, with an application time of 30 minutes. The device will be positioned with the spot located in the radial artery of the participant's arm (right or left), and fixed to the wrist with a specific bracelet.
Study NCT04835857 — intervention group
Intervention type: DEVICE
Intervention: ViTrack
Description: ViTrack is a continuous non-invasive wearable blood pressure cuff.
Study NCT04835857 — intervention group
Intervention type: DEVICE
Intervention: Oscillometric BP Device
Description: Oscillometric blood pressure measurement is the standard of care for measuring blood pressure in outpatient / home settings.
Study NCT04835857 — intervention group
Intervention type: DEVICE
Intervention: Auscultatory cuff
Description: The auscultatory method is the gold standard for clinical blood pressure measurement. A brachial cuff is mounted and a trained healthcare provider uses a sphygmomanometer and listens for the Korotkoff sounds using a stethoscope to measure blood pressure.
Study NCT06265454 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: low dose atropine eye drops
Description: Atropine is a nonselective muscarinic antagonist used for myopia control in previous studies.
Study NCT06265454 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT05638373 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: One shade universal composite
Description: A resin composite with new smart chromatic technology and chameleon effect. It has the ability to match the new lighter shade of the bleached teeth unlike the conventional composite
Study NCT05638373 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nanohybrid resin composite
Description: A conventional resin composite with multiple shades
Study NCT04625751 — intervention group
Intervention type: OTHER
Intervention: CO2-enriched air
Description: To assess cardiovascular reactivity
Study NCT04625751 — intervention group
Intervention type: OTHER
Intervention: Meal response test
Description: Meal response test to assess changes in splanchnic blood flow.
Study NCT05626946 — intervention group
Intervention type: OTHER
Intervention: Observation
Description: Observation
Study NCT06329102 — intervention group
Intervention type: PROCEDURE
Intervention: Surgical access
Description: Complications by Clavien Dindo Number of lymph nodes. Disease free and Overall survival
Study NCT04970654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: somapacitan
Description: Somapacitan (0.16 mg/kg/week) will be administered subcutaneously (s.c.; under the skin) once weekly by PDS290 pen-injector. Somapacitan can be injected any time during the once weekly dosing day. The dose will be calculated based on the subject's current body weight.
Study NCT04970654 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norditropin®
Description: Norditropin® (0.034 mg/kg/day) will be administered s.c. once daily by FlexPro® pen-injector. Norditropin® should be injected daily in the evening. The dose will be calculated based on the subject's current body weight.
Study NCT05233618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tagraxofusp
Description: inpatient on days 1-3 of cycles 1-4 and days 1-2 of additional cycles
Study NCT06308666 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delefilcon A contact lenses
Description: Daily disposable silicone hydrogel contact lenses indicated for the optical correction of myopia and hyperopia
Study NCT05751837 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lipopolysaccharide
Description: One tumor will be injected with 1 ug LPS (investigational drug) over approximately one minute
Study NCT05844280 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BFR+NMES at therapeutic level
Description: This group will receive therapy with BFR+NMES devices used at settings that are deemed by prior studies to be therapeutic.
Study NCT05844280 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: BFR+NMES at sub therapeutic level
Description: This means that the BFR tourniquet and the NMES device will be at such low settings as to not create the treatment effect but subject will have the equipments on their thigh during exercise
Study NCT05721170 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beta blocker
Description: Investigation on beta-blockers in TAVI and brief post-TAVI period.
Study NCT06059989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab subcutaneous
Description: Mono and combination therapy group
Study NCT06059989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunosuppressive Agents
Description: Combination group only
Study NCT05980325 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nordic Walking
Description: A 12-week Nordic Walking exercise programme supervised twice weekly
Study NCT05980325 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aquatic Exercise
Description: A 12-week water-based exercise training programme supervised twice weekly
Study NCT05980325 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Functional Exercise Training
Description: A 12-week circuit-based exercise training programme supervised twice weekly
Study NCT06286462 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cancer Tracking System (CATSystem)
Description: The CATSystem provider dashboard highlights patients with overdue services or those in need of outreach and sends automated, customized texts to support screening and treatment follow-up per national guidelines. Points of intervention and alerts include: cervical cancer screening and treatment counseling, initial and follow up cervical cancer screening per national guidelines, treatment for precancer and cancer, referral tracking and follow up. In addition, the CATSystem can securely store images of the cervix taken with colposcopes to allow for remote expert consultation if needed to correctly diagnose a patient or can be reviewed at clinical team meetings for input. Primary goals of the CATSystem are to increase rates of guideline-adherent cervical cancer screening/ rescreening and improve guideline-adherent treatment, referral, and follow-up rates of women with positive screens.
Study NCT06644235 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold Application
Description: Before DFU care, the patient was given an appropriate position and the materials (forceps, scalpel, sponge, pad, bandage, etc.) and the temperature of the 0.9% NaCl solution kept in the refrigerator for 24 hours were measured with an infrared thermometer (+4°C to +8°C) and taken to the treatment area. The solution was transferred to a 50 mL syringe in a sterile manner. The solution was instilled into the wound simultaneously with wound care (5-15 min).
Study NCT06571019 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cool roof
Description: Cool roofs are a heat-reflecting material that can be applied to existing household roofing in the form of a liquid-applied membrane. Cool roofs work by increasing solar reflectance (the ability to reflect the visible wavelengths of sunlight, reducing heat transfer to the surface) and thermal emittance (the ability to radiate absorbed solar energy) thereby reducing the amount of heat transferred into the home.
Study NCT05955885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flurbiprofen Oral Lozenge
Description: This commercially available, over-the-counter lozenge manufactured by Reckitt Benckiser contains flurbiprofen as the active ingredient and is registered for the short-term treatment of sore throat associated with upper respiratory tract infections in people over the age of 12 years.
Study NCT05955885 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Difflam
Description: This is a non-medicated, control lozenge that is the same flavour as the experimental lozenge that is marketed to help soothe dry, tickly throats while supporting the body's immune health.
Study NCT05955885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flurbiprofen 8.75 MG
Description: This commercially available, over-the-counter spray manufactured by Reckitt Benckiser contains flurbiprofen as the active ingredient and is registered for the short-term treatment of sore throat associated with upper respiratory tract infections in people over the age of 12 years. It requires 3 actuations of the spray to deliver the full 8.75 dose. Here, a low dose control can be delivered by only performing 1 actuation of the spray.
Study NCT05955885 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Flurbiprofen 8.75 MG
Description: This commercially available, over-the-counter spray manufactured by Reckitt Benckiser contains flurbiprofen as the active ingredient and is registered for the short-term treatment of sore throat associated with upper respiratory tract infections in people over the age of 12 years. It requires 3 actuations of the spray to deliver the full 8.75 dose. Here, a low dose control can be delivered by only performing 1 actuation of the spray.
Study NCT00547326 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: treated with osteopatic cranial techniques
Description: treated with osteopatic cranial techniques
Study NCT00547326 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Treatment with placebo
Description: Treatment with placebo
Study NCT05542589 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phenytoin phonophoresis
Description: Phenytoin phonophoresis for 5-10 minute sessions, three times per week and six weeks as a total period treatment.
Study NCT05542589 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham phenytoin phonophoresis
Description: Sham phenytoin phonophoresis for 5-10 minute sessions, three times per week and six weeks as a total period treatment.
Study NCT06355518 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Immunonutrition
Description: This formula is enriched in arginine, nucleotides (RNA) and omega-3 fatty acids and provides, with the proposed therapeutic volume (2 units per day), 36 grams of protein and 682 kcal/day.
Study NCT06355518 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard Oral Nutritional Supplement
Description: This formula provides 38 grams of protein and 500 kcal/day with the proposed therapeutic volume.
Study NCT05321342 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bullying Classroom Check-Up (BCCU)
Description: BCCU professional development (PD) modules will be provided to all staff in intervention schools as part of their standard, school-approved professional development practices to provide knowledge and awareness for bullying identification, prevention, and intervention. In addition, consented 3rd-5th grade teachers will participate in the BCCU intervention. The coaching follows the original Classroom Check-Up model (Reinke, Herman, \& Sprick, 2011), embedding 5 steps (i.e., assessment of the classroom, feedback to teacher, goal setting and plan, ongoing coaching and guided practice in the TeachLivE© mixed-reality simulator \[developed at the University of Central Florida \[UCF\]; Dieker, Hynes, Hughes, \& Smith, 2008\], and self-monitoring) and utilizing motivational interviewing (Miller \& Rollnick, 2012) to empower teacher practice change.
Study NCT04959266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adavosertib
Description: Patients will receive a single dose of Adavosertib orally in arm A, B, and C.
Study NCT04959266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Patients will receive Itraconazole orally once daily for 7 days in arm A.
Study NCT04959266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: Patients will receive Rifampicin orally once daily for 13 days in arm B.
Study NCT04959266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Patients will receive Omeprazole orally once daily for 5 days in arm C.